Quick Answer
ADMA BIOLOGICS, INC. reported Operating Income Loss of $191.44 million for the year ending 2025.
- ADMA BIOLOGICS, INC. showed an increase of +37.7% in Operating Income Loss from 2024 to 2025.
- This data is from ADMA BIOLOGICS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$1.59 million | Q2 2011: -$2.15 million | Q3 2011: -$768.2 thousand | Q1 2012: -$1.21 million | Q2 2012: -$1.21 million | Q3 2012: -$3.25 million | Q1 2013: -$3.15 million | Q2 2013: -$4.84 million | Q3 2013: -$2.53 million | Q1 2014: -$5.68 million | Q2 2014: -$3.59 million | Q3 2014: -$3.04 million | Q1 2015: -$3.20 million | Q2 2015: -$3.52 million | Q3 2015: -$4.66 million | Q1 2016: -$4.16 million | Q2 2016: -$5.49 million | Q3 2016: -$3.74 million | Q1 2017: -$5.94 million | Q2 2017: -$8.40 million | Q3 2017: -$14.43 million | Q1 2018: -$16.53 million | Q2 2018: -$13.42 million | Q3 2018: -$13.79 million | Q4 2018: -$16.55 million | Q1 2019: -$13.21 million | Q2 2019: -$11.34 million | Q3 2019: -$9.05 million | Q1 2020: -$16.77 million | Q2 2020: -$17.12 million | Q3 2020: -$13.80 million | Q1 2021: -$15.16 million | Q2 2021: -$15.58 million | Q3 2021: -$14.44 million | Q1 2022: -$14.82 million | Q2 2022: -$9.17 million | Q3 2022: -$9.32 million | Q1 2023: -$813.0 thousand | Q2 2023: -$473.0 thousand | Q3 2023: $8.69 million | Q1 2024: $21.82 million | Q2 2024: $39.20 million | Q3 2024: $39.64 million | Q1 2025: $34.88 million | Q2 2025: $42.80 million | Q3 2025: $51.01 million.
- Over the full 15 years of available data (2011 to 2025), ADMA BIOLOGICS, INC.'s Operating Income Loss has grown by 4,241.1%.
- Historical annual values: Fiscal year 2025: $191.44 million | Fiscal year 2024: $138.98 million | Fiscal year 2023: $21.63 million | Fiscal year 2022: -$39.37 million | Fiscal year 2021: -$58.37 million | Fiscal year 2020: -$64.91 million | Fiscal year 2019: -$41.42 million | Fiscal year 2018: -$60.29 million | Fiscal year 2017: -$39.31 million | Fiscal year 2016: -$17.33 million | Fiscal year 2015: -$15.51 million | Fiscal year 2014: -$16.02 million | Fiscal year 2013: -$15.04 million | Fiscal year 2012: -$7.91 million | Fiscal year 2011: -$4.62 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: